Visceral obesity, fat mass/muscle mass ratio and atherogenic dyslipidemia: cross-sectional study. Riobamba, Ecuador
DOI:
https://doi.org/10.14306/renhyd.19.3.154Keywords:
Visceral obesity, Fat mass/lean mass ratio, Atherogenic dyslipidemiaAbstract
Introduction: The distribution and composition of fat mass is associated with different metabolic risks. The predominance of brown visceral fat is associated with risk factors for cardiovascular disease (CVD), such as: high triglycerides and apolipoprotein B, increased LDL cholesterol, ratio triglycerides/low HDL cholesterol elevated (atherogenic dyslipidemia indicator), insulin resistance, hyperinsulinemia and cardiovascular risk (CVR). Sarcopenia and obesity may act synergistically in functional and metabolic disorders. The aim of this study was to determine the relationship between visceral obesity, fat mass/muscular mass ratio and atherogenic dyslipidemia in adult individuals in order to determine the association pattern between these variables and set strategies for focused attention.
Material and Methods: In a sample of 307 subjects of both sexes (21-71 years) there was measured atherogenic dyslipidemia as the ratio of triglyceride/HDL cholesterol, visceral obesity measured by bio impedance as the relative score of visceral fat, and the ratio fat mass/lean mass.
Results: A cluster analysis was performed to establish the structure of association between these variables with different risk groups. Three groups were identified: the first had visceral obesity with an average relative level of visceral fat of 13.6, the second group with an average of 8.9 and in the third group were placed individuals with the lowest visceral obesity score averaging 6.5. As for the fat mass/lean mas ratio the first two groups had a similar average of this index with a value of 1.56 and 1.69 respectively and the third group with the lowest average value of 1.3. Group 1 presented visceral obesity and impaired fat mass/lean mass ratio and had a high value of triglyceride/HDL ratio 4.1. Group 2 without visceral obesity and a deterioration in the relative fat mass/lean mass ratio had a triglyceride/HDL cholesterol of 3.6 and Group 3; not recorded visceral obesity or impaired fat mass/lean mass ratio had the lowest triglycerides/lower HDL ratio: 1.9.
Conclusions: It can be said that visceral obesity and the decrease in lean mass relative or absolute in relation to fat mass represents a high cardiovascular risk associated with atherogenic dyslipidemia, insulin resistance and cardiovascular risk.
References
(1) Popkin BM. La transición Nutricional y el cambio mundial hacia la obesidad. Diabetes Voice. 2014: 38–40.
(2) Freire WV, Ramírez MJ, Belmont P, Mendieta MJ, Silva MK, Romero N, et al. Resumen Ejecutivo Tomo 1 Encuesta Nacional de Salud y Nutrición del Ecuador. ENSANUT–ECU 2011–2013 [Revista en Internet] 2013 [consulta: 16/03/2015]. Disponible en: http://instituciones.msp.gob.ec/images/Documentos/varios/ENSANUT.pdf
(3) Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul). 2013; 28(2): 86–9.
(4) INEC. Anuario de estadistidisticas vitales: nacimientos y defunciones. INEC. [Revista en Internet]. 2013 [consulta: 16/03/2015]. Disponible en: www.ecuadorencifras.gob.ec/documentos/web-inec/Poblacion_y_Demografia/Nacimientos_Defunciones/Publicaciones/Anuario_Nacimientos_y_Defunciones_2013.pdf
(5) Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008; 11(6): 693–700.
(6) Roig, J. Obesidad y pérdida de tejido adiposo ''desterrando lo aeróbico''. Revista electrónica de ciencias aplicada al deporte. 2014; 21(6): 1–4.
(7) Buscemi J A. Sarcopenia, Sarcopenic Obesity and Insulin Resistence. En: Buscemi S, Batsis J. editores. Medical Complications of Type 2 Diabetes. Book edited by Collen Croniger. Shangai; 2011. p . 235–56.
(8) Goodpaster BH, Brown NF. Skeletal muscle lipid and its association with insulin resistance: what is the role for exercise? Exerc Sport Sci Rev. 2005; 33(3): 150–4.
(9) Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins AJ, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004; 27(4): 978–83.
(10) Reaven GM. Insulin Resistence, Carciovascular Disease, and the Metabolic Syndrome. Diabetes Care. 2004; 27(4): 1011–2.
(11) Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high–density lipoprotein, and risk of myocardial infarction. Circulation. 1997; 96(8): 2520–5.
(12) Quijada Z, Paoli M, Zerpa Y, Camacho N, Cichetti R, Villarroel V, et al. The triglyceride/HDL–cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes. 2008; 9(5): 464–71.
(13) Li C, Ford ES, Meng YX, Mokdad AH, Reaven GM. Does the association of the triglyceride to high–density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ ethnicity? Cardiovasc Diabetol. 2008; 7: 4.
(14) Hamrick MW, Herberg S, Arounleut P, He HZ, Shiver A, Qi RQ, et al. The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem Biophys Res Commun. 2010; 400(3): 379–83.
(15) Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010; 33(7): 1652–4.
(16) Murguía–Romero M, Jiménez–Flores JR, Sigrist–Flores SC, Espinoza–Camacho MA, Jiménez–Morales M, Piña E, et al. Plasma triglyceride/HDL–cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J Lipid Res. 2013; 54(10): 2795–9.
(17) Cruz–Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–23.
(18) González–Chávez A, Simental–Mendía LE, Elizondo–Argueta S. Elevated triglycerides/HDL–cholesterol ratio associated with insulin resistance. Cir Cir. 2011; 79(2): 126–31.
(19) de Giorgis T, Marcovecchio ML, Di Giovanni I, Giannini C, Chiavaroli V, Chiarelli F, et al. Triglycerides–to–HDL ratio as a new marker of endothelial dysfunction in obese prepubertal children. Eur J Endocrinol. 2013; 170(2): 173–80.
(20) Caballero R. Epidemiología de la dislipidemia aterogénica en un área urbana de la ciudad de Barcelona. Clin Invest Aterioscl. 2014; 26 (1): 17–9.
(21) Kim–Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M. Should triglycerides and the triglycerides to high–density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism. 2010; 59(2): 299–304.
(22) Gonzalez–Correa CH, Caicedo–Eraso JC, Villada–Gomez JS. Bioelectrical impedance amalysis (BIA) for sarcopenic obesity (SO) diagnosis in young female subjects. Journal of Physics. 2013: 1–4.
(23) Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a date set via the gap statistic. J R Statist Soc. 2001; 63(2): 411–23.
(24) Motulsky H. Prism 5 Statistics Guide. GraphPad Software inc. San Diego CA, www.graphpad.com.
(25) De la Fuente S. Análisis conglomerados. Madrid. Universidad Autónoma de Madrid; 1011 [acceso 13/02/2015]. Disponible en: http://www.fuenterrebollo.com/Economicas/ECONOMETRIA/SEGMENTACION/CONGLOMERADOS/conglomerados.pdf
(26) Zoratti R. A review on ethnic differences in plasma triglycerides and high–density–lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol. 1998; 14(1): 9–21.
(27) Kim TN, Park MS, Ryu JY, Choi HY, Hong HC, Yoo HJ, et al. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS). PLoS One. 2014; 9(12): e115407.
(28) Burrows R, Correa–Burrows P, Reyes M, Blanco E, Albala C, Gahagan S. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors. Public Health Nutr. 2015: 1–8.
(29) Ishii S, Tanaka T, Akishita M, Ouchi Y, Tuji T, Iijima K; Kashiwa study investigators. Metabolic syndrome, sarcopenia and role of sex and age: cross–sectional analysis of Kashiwa cohort study. PLoS One. 2014; 9(11): e112718.
This journal 